ByHeart, Inc., Infant Formula Marketing, Sales Practices, and Products Liability Litigation
Infant botulism caused by *Clostridium botulinum* in formula involves ingestion of spores, colonization in the infant's gut, and toxin production, with symptoms developing within 3 to 30 days. Diagnosis relies on clinical signs such as muscle weakness, paralysis, and respiratory issues, supported by laboratory detection of toxin or spores in stool. Early recognition and treatment with antitoxin are critical. Outbreaks linked to contaminated ByHeart formula prompted recalls and investigations by FDA and CDC, emphasizing the importance of prompt diagnosis and intervention (Sources: [FDA](https://www.fda.gov/food/outbreaks-foodborne-illness/outbreak-investigation-infant-botulism-infant-formula-november-2025), [CDC](https://www.cdc.gov/botulism/outbreaks-investigations/infant-formula-nov-2025/investigation.html)).
21
Pending actions
21
Total actions filed
Active
Status
04/02/2026
Established
Filing deadline
No specific filing deadlines publicly announced; initial case filings date from January 15, 2026, with procedural deadlines likely set in the initial case management order, which is not publicly detailed.
Who qualifies
Plaintiffs must demonstrate that their child consumed the specific recalled batches of ByHeart infant formula during the contamination period and subsequently developed symptoms consistent with infant botulism, confirmed by laboratory testing of stool for *Clostridium botulinum* toxin or spores. Medical records confirming diagnosis are required. Exposure must be linked to the specific batches identified in recall notices, with symptoms appearing within the typical incubation period of 3 to 30 days post-exposure.
Products involved
- ByHeart Whole Nutrition Infant Formula
Alleged injuries
- Infant botulism
- Necrotizing enterocolitis (NEC) in some cases
Bellwether trials
No specific bellwether trial dates or recent verdicts publicly announced; ongoing case management and consolidation efforts are reported, with scheduled bellwether trials extending into early 2027 but no definitive dates set as of the latest updates (Sources: [Harrismartin](https://www.harrismartin.com/publications/27/MDL/articles/42210/bellwether-trials-scheduled-in-preterm-infant-formula-mdl), [Top Class Actions](https://topclassactions.com/lawsuit-settlements/lawsuit-news/byheart-infant-formula-class-action-lawsuits-consolidated-in-new-mdl)).
Settlement landscape
No publicly available settlement amounts or case values; ongoing litigation and investigations suggest potential for future settlements, but no specific figures are disclosed.
Lead counsel
- Law firms involved are not explicitly identified in publicly available court documents; further review of full orders needed for definitive names.
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
